Adapting the Rx-Risk-V for mortality prediction in outpatient populations

Michael L. Johnson, Hashem B. El-Serag, Tung Thomas Tran, Christine Hartman, Peter Richardson, Neena Susan Abraham

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objectives: We sought to operationalize, test, and validate an outpatient pharmacy-based case-mix adjuster. Methods: Outpatients from the Department of Veterans Affairs (VA) prescribed a nonsteroidal anti-inflammatory drug (NSAID) or cyclooxygenase-2 selective drug during 2002 were identified. We updated and extended the Rx-Risk-V by adding 26 additional disease categories and mapping them to VA drug-class codes; derived empirical weights for each from a logistic model of 1-year mortality; adjusted for age, race and sex; and scored the weights into 1 measure of comorbidity. We compared the weighted score to the Deyo diagnosis-based comorbidity index and validated it in a national cohort of 260,321 outpatients with chronic heart failure (CHF). Results: One-year mortality among the 724,270-outpatient NSAID cohort was 1.6% (n ≤ 11,766). Using a baseline model of age, race, and gender (c-index ≤ 0.716), we found that the Deyo measure improved the prediction of mortality (c-index ≤ 0.765), and the pharmacy comorbidity score further improved the prediction (c-index ≤ 0.782), an increase of 25.8%. Using both, we found further improvement (c-index ≤ 0.792). Among the CHF cohort, 9.7% (n ≤ 25,251) died within 1 year. Performance of the baseline model controlling for age, race, and gender (c index ≤ 0.620) improved with addition of the pharmacy comorbidity score (c index ≤ 0.689), compared with the addition of the Deyo measure (c index ≤ 0.651), an increase of 55.1%. Together, they slightly improved prediction in CHF patients (c index ≤ 0.695). Conclusions: The updated and extended Rx-Risk-V is useful for case-mix adjustment of mortality in an outpatient population.

Original languageEnglish (US)
Pages (from-to)793-797
Number of pages5
JournalMedical Care
Volume44
Issue number8
DOIs
StatePublished - Aug 2006
Externally publishedYes

Fingerprint

Outpatients
mortality
Comorbidity
Mortality
comorbidity
Heart Failure
Population
Veterans
Pharmaceutical Preparations
Anti-Inflammatory Agents
drug
Risk Adjustment
Weights and Measures
Diagnosis-Related Groups
Cyclooxygenase 2
Logistic Models
gender
logistics
Disease
performance

Keywords

  • Case-mix adjustment
  • Co-morbidity in outpatients
  • Mortality prediction
  • Outcomes prediction
  • Rx-Risk-V

ASJC Scopus subject areas

  • Nursing(all)
  • Public Health, Environmental and Occupational Health
  • Health(social science)
  • Health Professions(all)

Cite this

Johnson, M. L., El-Serag, H. B., Tran, T. T., Hartman, C., Richardson, P., & Abraham, N. S. (2006). Adapting the Rx-Risk-V for mortality prediction in outpatient populations. Medical Care, 44(8), 793-797. https://doi.org/10.1097/01.mlr.0000218804.41758.ef

Adapting the Rx-Risk-V for mortality prediction in outpatient populations. / Johnson, Michael L.; El-Serag, Hashem B.; Tran, Tung Thomas; Hartman, Christine; Richardson, Peter; Abraham, Neena Susan.

In: Medical Care, Vol. 44, No. 8, 08.2006, p. 793-797.

Research output: Contribution to journalArticle

Johnson, ML, El-Serag, HB, Tran, TT, Hartman, C, Richardson, P & Abraham, NS 2006, 'Adapting the Rx-Risk-V for mortality prediction in outpatient populations', Medical Care, vol. 44, no. 8, pp. 793-797. https://doi.org/10.1097/01.mlr.0000218804.41758.ef
Johnson, Michael L. ; El-Serag, Hashem B. ; Tran, Tung Thomas ; Hartman, Christine ; Richardson, Peter ; Abraham, Neena Susan. / Adapting the Rx-Risk-V for mortality prediction in outpatient populations. In: Medical Care. 2006 ; Vol. 44, No. 8. pp. 793-797.
@article{ed7b06a658dc4991a44d78765c02d3d3,
title = "Adapting the Rx-Risk-V for mortality prediction in outpatient populations",
abstract = "Objectives: We sought to operationalize, test, and validate an outpatient pharmacy-based case-mix adjuster. Methods: Outpatients from the Department of Veterans Affairs (VA) prescribed a nonsteroidal anti-inflammatory drug (NSAID) or cyclooxygenase-2 selective drug during 2002 were identified. We updated and extended the Rx-Risk-V by adding 26 additional disease categories and mapping them to VA drug-class codes; derived empirical weights for each from a logistic model of 1-year mortality; adjusted for age, race and sex; and scored the weights into 1 measure of comorbidity. We compared the weighted score to the Deyo diagnosis-based comorbidity index and validated it in a national cohort of 260,321 outpatients with chronic heart failure (CHF). Results: One-year mortality among the 724,270-outpatient NSAID cohort was 1.6{\%} (n ≤ 11,766). Using a baseline model of age, race, and gender (c-index ≤ 0.716), we found that the Deyo measure improved the prediction of mortality (c-index ≤ 0.765), and the pharmacy comorbidity score further improved the prediction (c-index ≤ 0.782), an increase of 25.8{\%}. Using both, we found further improvement (c-index ≤ 0.792). Among the CHF cohort, 9.7{\%} (n ≤ 25,251) died within 1 year. Performance of the baseline model controlling for age, race, and gender (c index ≤ 0.620) improved with addition of the pharmacy comorbidity score (c index ≤ 0.689), compared with the addition of the Deyo measure (c index ≤ 0.651), an increase of 55.1{\%}. Together, they slightly improved prediction in CHF patients (c index ≤ 0.695). Conclusions: The updated and extended Rx-Risk-V is useful for case-mix adjustment of mortality in an outpatient population.",
keywords = "Case-mix adjustment, Co-morbidity in outpatients, Mortality prediction, Outcomes prediction, Rx-Risk-V",
author = "Johnson, {Michael L.} and El-Serag, {Hashem B.} and Tran, {Tung Thomas} and Christine Hartman and Peter Richardson and Abraham, {Neena Susan}",
year = "2006",
month = "8",
doi = "10.1097/01.mlr.0000218804.41758.ef",
language = "English (US)",
volume = "44",
pages = "793--797",
journal = "Medical Care",
issn = "0025-7079",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Adapting the Rx-Risk-V for mortality prediction in outpatient populations

AU - Johnson, Michael L.

AU - El-Serag, Hashem B.

AU - Tran, Tung Thomas

AU - Hartman, Christine

AU - Richardson, Peter

AU - Abraham, Neena Susan

PY - 2006/8

Y1 - 2006/8

N2 - Objectives: We sought to operationalize, test, and validate an outpatient pharmacy-based case-mix adjuster. Methods: Outpatients from the Department of Veterans Affairs (VA) prescribed a nonsteroidal anti-inflammatory drug (NSAID) or cyclooxygenase-2 selective drug during 2002 were identified. We updated and extended the Rx-Risk-V by adding 26 additional disease categories and mapping them to VA drug-class codes; derived empirical weights for each from a logistic model of 1-year mortality; adjusted for age, race and sex; and scored the weights into 1 measure of comorbidity. We compared the weighted score to the Deyo diagnosis-based comorbidity index and validated it in a national cohort of 260,321 outpatients with chronic heart failure (CHF). Results: One-year mortality among the 724,270-outpatient NSAID cohort was 1.6% (n ≤ 11,766). Using a baseline model of age, race, and gender (c-index ≤ 0.716), we found that the Deyo measure improved the prediction of mortality (c-index ≤ 0.765), and the pharmacy comorbidity score further improved the prediction (c-index ≤ 0.782), an increase of 25.8%. Using both, we found further improvement (c-index ≤ 0.792). Among the CHF cohort, 9.7% (n ≤ 25,251) died within 1 year. Performance of the baseline model controlling for age, race, and gender (c index ≤ 0.620) improved with addition of the pharmacy comorbidity score (c index ≤ 0.689), compared with the addition of the Deyo measure (c index ≤ 0.651), an increase of 55.1%. Together, they slightly improved prediction in CHF patients (c index ≤ 0.695). Conclusions: The updated and extended Rx-Risk-V is useful for case-mix adjustment of mortality in an outpatient population.

AB - Objectives: We sought to operationalize, test, and validate an outpatient pharmacy-based case-mix adjuster. Methods: Outpatients from the Department of Veterans Affairs (VA) prescribed a nonsteroidal anti-inflammatory drug (NSAID) or cyclooxygenase-2 selective drug during 2002 were identified. We updated and extended the Rx-Risk-V by adding 26 additional disease categories and mapping them to VA drug-class codes; derived empirical weights for each from a logistic model of 1-year mortality; adjusted for age, race and sex; and scored the weights into 1 measure of comorbidity. We compared the weighted score to the Deyo diagnosis-based comorbidity index and validated it in a national cohort of 260,321 outpatients with chronic heart failure (CHF). Results: One-year mortality among the 724,270-outpatient NSAID cohort was 1.6% (n ≤ 11,766). Using a baseline model of age, race, and gender (c-index ≤ 0.716), we found that the Deyo measure improved the prediction of mortality (c-index ≤ 0.765), and the pharmacy comorbidity score further improved the prediction (c-index ≤ 0.782), an increase of 25.8%. Using both, we found further improvement (c-index ≤ 0.792). Among the CHF cohort, 9.7% (n ≤ 25,251) died within 1 year. Performance of the baseline model controlling for age, race, and gender (c index ≤ 0.620) improved with addition of the pharmacy comorbidity score (c index ≤ 0.689), compared with the addition of the Deyo measure (c index ≤ 0.651), an increase of 55.1%. Together, they slightly improved prediction in CHF patients (c index ≤ 0.695). Conclusions: The updated and extended Rx-Risk-V is useful for case-mix adjustment of mortality in an outpatient population.

KW - Case-mix adjustment

KW - Co-morbidity in outpatients

KW - Mortality prediction

KW - Outcomes prediction

KW - Rx-Risk-V

UR - http://www.scopus.com/inward/record.url?scp=33747866940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747866940&partnerID=8YFLogxK

U2 - 10.1097/01.mlr.0000218804.41758.ef

DO - 10.1097/01.mlr.0000218804.41758.ef

M3 - Article

C2 - 16862043

AN - SCOPUS:33747866940

VL - 44

SP - 793

EP - 797

JO - Medical Care

JF - Medical Care

SN - 0025-7079

IS - 8

ER -